Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A thiazole compound with potential antithrombotic activity

E E Nishizawa, A R Mendoza, T Honohan

    Thrombosis and Haemostasis
    |April 30, 1982
    PubMed
    Summary

    A novel thiazole derivative effectively inhibits platelet aggregation across multiple species, showing promise as an antithrombotic agent. This compound demonstrates potent antiplatelet activity with low toxicity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The split denture: a new technique for artificial saliva reservoirs in mandibular dentures.

    Australian dental journal·2003
    Same author

    Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module). A mechanism for gene deletions and disease associations.

    The Journal of biological chemistry·1999
    Same author

    Guidelines for quality assurance in multicenter trials: a position paper.

    Controlled clinical trials·1998
    Same author

    Human helicase gene SKI2W in the HLA class III region exhibits striking structural similarities to the yeast antiviral gene SKI2 and to the human gene KIAA0052: emergence of a new gene family.

    Nucleic acids research·1995
    Same author

    Complement component C4 gene intron 9 as a phylogenetic marker for primates: long terminal repeats of the endogenous retrovirus ERV-K(C4) are a molecular clock of evolution.

    Immunogenetics·1995
    Same author

    Structure and genetics of the partially duplicated gene RP located immediately upstream of the complement C4A and the C4B genes in the HLA class III region. Molecular cloning, exon-intron structure, composite retroposon, and breakpoint of gene duplication.

    The Journal of biological chemistry·1994

    Area of Science:

    • Medicinal Chemistry
    • Pharmacology
    • Biochemistry

    Background:

    • Platelet aggregation plays a crucial role in thrombosis.
    • Developing potent and safe antithrombotic agents is a significant medical need.
    • Thiazole derivatives have shown potential in various therapeutic areas.

    Purpose of the Study:

    • To evaluate the antiplatelet and anti-inflammatory activities of a novel thiazole derivative.
    • To assess the in vivo efficacy and safety profile of the compound.
    • To explore its potential as an antithrombotic agent.

    Main Methods:

    • In vitro assessment of collagen-induced platelet aggregation in human and animal platelets.
    • Comparison of antiplatelet activity with flurbiprofen.
    • Evaluation of cyclooxygenase activity.

    Related Experiment Videos

  • In vivo antiplatelet activity assessment after oral administration in laboratory species.
  • Determination of LD50 in mice.

    • Main Results:

    • The thiazole derivative potently inhibited collagen-induced platelet aggregation in vitro across six species, including humans, at concentrations as low as 1 ng/ml.
    • Its antiplatelet activity in human platelet-rich plasma exceeded that of flurbiprofen.
    • The compound demonstrated significant in vivo antiplatelet activity following oral administration in five species.
    • The LD50 in mice was >1000 mg/kg (i.p.), indicating a favorable safety profile.
    • Compared to flurbiprofen, the thiazole derivative exhibited less anti-inflammatory activity in the hind-paw edema test.

    Conclusions:

    • The novel thiazole derivative is a potent inhibitor of platelet aggregation with broad species activity.
    • It possesses a favorable safety profile and efficacy following oral administration.
    • This compound represents a promising candidate for the development of new antithrombotic therapies.